About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Vhltm1.1Lss
targeted mutation 1.1, Laura S Schmidt
MGI:2677579
Summary 5 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
ht1
Vhltm1.1Lss/Vhl+ involves: A/J MGI:2677768
ht2
Vhltm1.1Lss/Vhl+ involves: BALB/c MGI:2677767
ht3
Vhltm1Lss/Vhltm1.1Lss involves: 129X1/SvJ * C57BL/6 MGI:2677761
cn4
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
involves: 129S1/Sv * 129X1/SvJ MGI:3653510
cn5
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
involves: 129X1/SvJ * C3H * C57BL/6 MGI:2677759


Genotype
MGI:2677768
ht1
Allelic
Composition
Vhltm1.1Lss/Vhl+
Genetic
Background
involves: A/J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (16 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
liver/biliary system
• 66% showed hepatic vascular lesions on a A/J genetic background

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513




Genotype
MGI:2677767
ht2
Allelic
Composition
Vhltm1.1Lss/Vhl+
Genetic
Background
involves: BALB/c
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (16 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 88% showed hepatic hemangiomas by 18 months of age, on a BALB/c genetic background

liver/biliary system
• 88% showed hepatic hemangiomas by 18 months of age, on a BALB/c genetic background

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513




Genotype
MGI:2677761
ht3
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Genetic
Background
involves: 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Vhltm1.1Lss mutation (0 available); any Vhl mutation (16 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (16 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

reproductive system
• 2-fold reduction in sperm count relative to wild-type

liver/biliary system
• observed in 18% of mice between 4 and 12 months of age, putatively due to sporadic LOH
• smaller than those observed in Vhlhtm1Lss/ Vhlhtm1.1Lss;Tg(ACTB-cre)1Tes mice

cellular
• 2-fold reduction in sperm count relative to wild-type

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513




Genotype
MGI:3653510
cn4
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(CAG-cre/Esr1*)1Lbe/0
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(CAG-cre/Esr1*)1Lbe mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (16 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (16 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• all embryos of pregnant females injected with 2 mg of tamoxifen at E10.5 to inactive Vhlh during mid-gestational stage, die between E14.5 and E15.5

growth/size/body
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls

cardiovascular system
• treatment of pregnant females at E10.5 with tamoxifen results in abnormal vasculature and dilated blood vessels in the body of E14.7 embryos
• dilated vessels are frequently seen after tamoxifen treatment
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• treatment of pregnant females at E10.5 with tamoxifen results in hemorrhage in the dorsolateral region of embryos at E14.5

cellular
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos

embryo
• treatment of pregnant females at E10.5 with tamoxifen results in impaired blood circulation in the yolk sac of E14.7 embryos
• treatment of pregnant females at E10.5 with tamoxifen results in extensive embryo necrosis
• embryos of pregnant females injected with tamoxifen at E10.5 are smaller than controls
• when pregnant females are injected with tamoxifen at E10.5, frequently observe dilated blood vessels and spongiotriophoblast cells in the labyrinthine layer
• dilated vessels are frequently seen after tamoxifen treatment
• thickness of the labyrinthine layer is reduced when pregnant females are injected with tamoxifen at E10.5

liver/biliary system
• treatment of pregnant females at E10.5 with tamoxifen results in focal necrosis in the liver or E14.5 embryos

integument
• seen in embryos of pregnant females injected with tamoxifen at E10.5

homeostasis/metabolism
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly lower serum creatinine levels than tamoxifen-treated control mice (0.24 +/- 0.04 mg/dl versus 0.72 +/- 0.16 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice exhibit significantly lower serum BUN levels than tamoxifen-treated control mice (52.12 +/- 6.61 mg/dl versus 138.10 +/- 13.03 mg/dL, respectively)
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration

renal/urinary system
• at 24 hrs after bilateral renal ischemia-reperfusion injury (IRI), tamoxifen-treated mice exhibit significantly fewer TUNEL+ cells in the proximal tubules relative to tamoxifen-treated control mice
• at 24 hrs after bilateral renal IRI, tamoxifen-treated mice (0.36mg/g body weight injected i.p. one wk prior to IRI) exhibit better preservation of renal function and significantly lower tubular injury scores than tamoxifen-treated control mice (2.40 +/- 0.08 and 0.90 +/- 0.12, respectively), consistent with reduced proximal tubular injury, near absence of TUNEL+ cells, and milder tubular epithelial degeneration




Genotype
MGI:2677759
cn5
Allelic
Composition
Vhltm1Lss/Vhltm1.1Lss
Tg(ACTB-cre)1Tes/0
Genetic
Background
involves: 129X1/SvJ * C3H * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(ACTB-cre)1Tes mutation (0 available)
Vhltm1.1Lss mutation (0 available); any Vhl mutation (16 available)
Vhltm1Lss mutation (0 available); any Vhl mutation (16 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice began to die after 3 months of age
• 50% mortalitiy exhibited by 7 months of age
• 90% mortalitiy by 1 year of age

reproductive system
• 30-fold reduction in sperm count relative to wild-type
• abnormal sperm maturation with multinucleated giant cells
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse

neoplasm
• all mice displayed grossly visible hemangiomas by 1 year of age

cardiovascular system
• frequent angiectasis in the liver and with lesser penetrance in the kidneys
• increased vasculature of the pancreas
• no vascular lesions observed in the brain, ovary, or adrenal glands
• limited new blood vessel formation in the liver
• angiogenesis observed the cardiac muscle of 8 of 10 mice examined

liver/biliary system
• livers were irregularly shaped and had vascular lesions containing large, thin-walled vessels filled with blood
• all mice displayed grossly visible hemangiomas by 1 year of age

endocrine/exocrine glands
• enlarged blood vessels in the connective tissue surrounding the tubules
• tubule atrophy and collapse

cellular
• 30-fold reduction in sperm count relative to wild-type
• abnormal sperm maturation with multinucleated giant cells

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
von Hippel-Lindau disease DOID:14175 OMIM:193300
J:85513





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
03/12/2024
MGI 6.23
The Jackson Laboratory